Market open

Jasper Therapeutics/$JSPR

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Jasper Therapeutics

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Ticker

$JSPR
Trading on

Industry

Biotechnology

Employees

45

JSPR Metrics

BasicAdvanced
$354M
Market cap
-
P/E ratio
-$4.67
EPS
2.20
Beta
-
Dividend rate
$354M
2.2
$31.01
$4.00
244K
7.609
7.445
1.207
2.473
-40.92%
-71.46%
4.23
4.23
-5.477
-34.28%
-65.68%

What the Analysts think about JSPR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Jasper Therapeutics stock.

JSPR Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

JSPR Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $JSPR

$

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Jasper Therapeutics stock?

Jasper Therapeutics (JSPR) has a market cap of $354M as of December 04, 2024.

What is the P/E ratio for Jasper Therapeutics stock?

The price to earnings (P/E) ratio for Jasper Therapeutics (JSPR) stock is 0 as of December 04, 2024.

Does Jasper Therapeutics stock pay dividends?

No, Jasper Therapeutics (JSPR) stock does not pay dividends to its shareholders as of December 04, 2024.

When is the next Jasper Therapeutics dividend payment date?

Jasper Therapeutics (JSPR) stock does not pay dividends to its shareholders.

What is the beta indicator for Jasper Therapeutics?

Jasper Therapeutics (JSPR) has a beta rating of 2.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.